Available vaccines for influenza virus induce antibodies targeting hemagglutinin protein which is present on the virus surface which are strain-specific and are poorly effective. To counteract this problem, yearly influenza virus vaccinations should be updated or modified according to the new strain which might be expensive. Moreover, there also exist avian influenza viruses which are highly pathogenic with high fatality rates i.e. Universal vaccines are better due to several of their optimal properties including adequate immune protection, affordable financing as well as effective production methods. Therefore, a novel strategy to target this receptor has been introduced recently for which a monoclonal antibody was developed which attaches to CDC1 cells. Furthermore, several M2e protein copies were attached to it which is a universal antigen for flu. So, the developed vaccine was Clec9A-M2e which was found effective in combating the infection in mouse models. For instance, a small dosage of this vaccine upon administration to mice was able to trigger a longterm immune response against M2e protein and further protection upon exposure to the influenza virus. Moreover, the vaccine was also able to boost the antibodies against M2e protein in mice having flu previously. Therefore, it can be inferred from the study this Clec9A targeting method is an effective strategy for addressing the limitations of vaccines targeting M2e protein and these might be generalized to humans .